Brind.

Nomura rates Torrent Pharmaceuticals 'Neutral' amid strong Indian Pharma Market growth

1 report, 1 independent Updated Oct 9
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Nomura rated Torrent Pharmaceuticals 'Neutral' in its October 8 note. The brokerage highlighted that the Indian Pharmaceutical Market recorded 13.5% year-on-year growth in September, its strongest performance in three years. Nomura retained 'Buy' ratings on Sun Pharmaceutical Industries, Lupin, Zydus Lifesciences, and Dr Reddy's Laboratories.

From moneycontrol.com

Why it matters

Some supportBrind's analysis of the reports

The strong growth in the Indian Pharmaceutical Market confirms the health of the sector in India. While Torrent Pharmaceuticals received a 'Neutral' rating, Zydus Lifesciences and Sun Pharmaceutical Industries led growth among top companies, with sales rising 23.5% and 21.5% year-on-year, respectively.

From moneycontrol.com

Who's involved

  • NomuraProvided financial ratings and analysis on Torrent Pharmaceuticals
  • Torrent PharmaceuticalsIndian multinational pharmaceutical company rated by Nomura

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped